About this episode
Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How much will it cost us? But Riley Griffin and Emma Court report that the Pharmaceutical industry is hoping Covid-19 will give it a chance to rebrand; and get the focus off drug prices.
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time Prognosis: Misconception publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Prognosis: Misconception
Introducing: Levittown
Prognosis: Misconception
Listen Now: Beak Capitalism from Odd Lots
Prognosis: Misconception
Misconception: Great Expectations
Prognosis: Misconception
Misconception: Big Baby
Prognosis: Misconception